{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:31:02Z","timestamp":1785493862428,"version":"3.56.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spectrum Health-Michigan State University Alliance Corporation funds to A.S.B"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-14-156-01-CDD"],"award-info":[{"award-number":["RSG-14-156-01-CDD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI","award":["R41 CA213488"],"award-info":[{"award-number":["R41 CA213488"]}]},{"name":"NIH\/NCI","award":["R42 CA213488"],"award-info":[{"award-number":["R42 CA213488"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.leukres.2019.106271","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T11:59:07Z","timestamp":1573559947000},"page":"106271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo"],"prefix":"10.1016","volume":"88","author":[{"given":"Marquicia R.","family":"Pierce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeder M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannya R.","family":"Ibarra-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Pirrung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan G.","family":"Dolloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-8560","authenticated-orcid":false,"given":"Andr\u00e9 S.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. (1)","key":"10.1016\/j.leukres.2019.106271_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.leukres.2019.106271_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2019.106271_bib0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.leukres.2019.106271_bib0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbpa.2014.08.012","article-title":"Subunit specific inhibitors of proteasomes and their potential for immunomodulation","volume":"23","author":"Kisselev","year":"2014","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"1","key":"10.1016\/j.leukres.2019.106271_bib0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: an expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem. Biol."},{"issue":"1","key":"10.1016\/j.leukres.2019.106271_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tibs.2013.10.004","article-title":"The unique functions of tissue-specific proteasomes","volume":"39","author":"Kniepert","year":"2014","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.leukres.2019.106271_bib0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","article-title":"The immunoproteasome and thymoproteasome: functions, evolution and human disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2019.106271_bib0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.chembiol.2008.04.010","article-title":"Joining the army of proteasome inhibitors","volume":"15","author":"Kisselev","year":"2008","journal-title":"Chem. Biol."},{"issue":"8","key":"10.1016\/j.leukres.2019.106271_bib0045","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/07357900701579570","article-title":"The role of bortezomib in the treatment of lymphoma","volume":"25","author":"Barr","year":"2007","journal-title":"Cancer Invest."},{"issue":"3","key":"10.1016\/j.leukres.2019.106271_bib0050","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"12","key":"10.1016\/j.leukres.2019.106271_bib0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14789450.2018.1543595","article-title":"The power of proteasome inhibition in multiple myeloma","volume":"15","author":"Guerrero-Garcia","year":"2018","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.leukres.2019.106271_bib0060","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-med-112017-091045","article-title":"New drugs in multiple myeloma","volume":"70","author":"Kunacheewa","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.leukres.2019.106271_bib0065","first-page":"23","article-title":"Targeted treatments for multiple myeloma: specific role of carfilzomib","volume":"8","author":"Sugumar","year":"2015","journal-title":"Pers. Med."},{"issue":"3","key":"10.1016\/j.leukres.2019.106271_bib0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10147-015-0826-3","article-title":"Current therapeutic strategies for multiple myeloma","volume":"20","author":"Torimoto","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"Suppl. (35)","key":"10.1016\/j.leukres.2019.106271_bib0075","article-title":"Cardiovascular adverse events in multiple myeloma patients","volume":"10","author":"Heckmann","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.leukres.2019.106271_bib0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2019.106271_bib0085","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.leukres.2019.106271_bib0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zajaczkowska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.leukres.2019.106271_bib0095","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7188","key":"10.1016\/j.leukres.2019.106271_bib0100","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nature06782","article-title":"A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism","volume":"452","author":"Groll","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.leukres.2019.106271_bib0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2184.2006.00402.x","article-title":"A new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis","volume":"39","author":"Coleman","year":"2006","journal-title":"Cell Prolif."},{"key":"10.1016\/j.leukres.2019.106271_bib0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0944-5013(99)80040-8","article-title":"Identification and structure of a family of syringolin variants: unusual cyclic peptides from Pseudomonas syringae pv. syringae that elicit defense responses in rice","volume":"154","author":"Waspi","year":"1999","journal-title":"Microbiol. Res."},{"issue":"11","key":"10.1016\/j.leukres.2019.106271_bib0115","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1039\/c1np00048a","article-title":"The chemistry and biology of syringolins, glidobactins and cepafungins (syrbactins)","volume":"28","author":"Krahn","year":"2011","journal-title":"Nat. Prod. Rep."},{"issue":"1","key":"10.1016\/j.leukres.2019.106271_bib0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.tim.2013.10.010","article-title":"The role of bacterial phytotoxins in inhibiting the eukaryotic proteasome","volume":"22","author":"Dudler","year":"2014","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.leukres.2019.106271_bib0125","first-page":"247","article-title":"Proteasome inhibitors in pediatric cancer treatment","volume":"67","author":"Bachmann","year":"2008","journal-title":"Hawaii Med. J."},{"issue":"10","key":"10.1016\/j.leukres.2019.106271_bib0130","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.7164\/antibiotics.41.1358","article-title":"Enhanced production of the minor components of glidobactins in Polyangium brachysporum","volume":"41","author":"Numata","year":"1988","journal-title":"J. Antibiot."},{"issue":"10","key":"10.1016\/j.leukres.2019.106271_bib0135","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.7164\/antibiotics.41.1351","article-title":"Enzymatic formation of glidobactamine: a peptide nucleus of glidobactins A, B and C, new lipopeptide antitumor antibiotics","volume":"41","author":"Numata","year":"1988","journal-title":"J. Antibiot."},{"issue":"10","key":"10.1016\/j.leukres.2019.106271_bib0140","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.7164\/antibiotics.41.1331","article-title":"Glidobactins A, B and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity","volume":"41","author":"Oka","year":"1988","journal-title":"J. Antibiot."},{"issue":"12","key":"10.1016\/j.leukres.2019.106271_bib0145","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.7164\/antibiotics.41.1906","article-title":"Glidobactins D, E, F, G and H; minor components of the antitumor antibiotic glidobactin","volume":"41","author":"Oka","year":"1988","journal-title":"J. Antibiot."},{"issue":"10","key":"10.1016\/j.leukres.2019.106271_bib0150","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.7164\/antibiotics.41.1338","article-title":"Glidobactins A, B and C, new antitumor antibiotics. II. Structure elucidation","volume":"41","author":"Oka","year":"1988","journal-title":"J. Antibiot."},{"issue":"7","key":"10.1016\/j.leukres.2019.106271_bib0155","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7164\/antibiotics.43.783","article-title":"Isolation of cepafungins I, II and III from Pseudomonas species","volume":"43","author":"Shoji","year":"1990","journal-title":"J. Antibiot."},{"issue":"7","key":"10.1016\/j.leukres.2019.106271_bib0160","doi-asserted-by":"crossref","first-page":"788","DOI":"10.7164\/antibiotics.43.788","article-title":"Structures of cepafungins I, II and III","volume":"43","author":"Terui","year":"1990","journal-title":"J. Antibiot."},{"issue":"16","key":"10.1016\/j.leukres.2019.106271_bib0165","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1073\/pnas.0901982106","article-title":"Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition","volume":"106","author":"Clerc","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/j.leukres.2019.106271_bib0170","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1021\/ol101252y","article-title":"Total synthesis of syringolin A","volume":"12","author":"Dai","year":"2010","journal-title":"Org. Lett."},{"issue":"10","key":"10.1016\/j.leukres.2019.106271_bib0175","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/ol100761z","article-title":"Total synthesis of syringolin A and B","volume":"12","author":"Pirrung","year":"2010","journal-title":"Org. Lett."},{"issue":"34","key":"10.1016\/j.leukres.2019.106271_bib0180","doi-asserted-by":"crossref","first-page":"6880","DOI":"10.1021\/bi300841r","article-title":"Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells","volume":"51","author":"Archer","year":"2012","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.leukres.2019.106271_bib0185","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bcp.2010.03.031","article-title":"Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt\/PKB activation in neuroblastoma","volume":"80","author":"Archer","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"16","key":"10.1016\/j.leukres.2019.106271_bib0190","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1074\/jbc.M115.710053","article-title":"Syrbactin structural analog TIR-199 blocks proteasome activity and induces tumor cell death","volume":"291","author":"Bachmann","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.leukres.2019.106271_bib0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bmc.2017.11.048","article-title":"Immunoproteasome inhibition and bioactivity of thiasyrbactins","volume":"26","author":"Bakas","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"16","key":"10.1016\/j.leukres.2019.106271_bib0200","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cbic.200900411","article-title":"Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines","volume":"10","author":"Clerc","year":"2009","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.leukres.2019.106271_bib0205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1039\/C0CC02238A","article-title":"The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity","volume":"47","author":"Clerc","year":"2011","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.leukres.2019.106271_bib0210","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1002\/ejoc.201000317","article-title":"Convergent synthesis and biological evaluation of Syringolin A and derivatives as eukaryotic 20S proteasome inhibitors","volume":"21","author":"Clerc","year":"2010","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.leukres.2019.106271_bib0215","doi-asserted-by":"crossref","first-page":"9950","DOI":"10.1016\/j.tet.2011.09.048","article-title":"Syntheses and cytotoxicity of syringolin B-based proteasome inhibitors","volume":"67","author":"Ibarra-Rivera","year":"2011","journal-title":"Tetrahedron"},{"issue":"1","key":"10.1016\/j.leukres.2019.106271_bib0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/13880209.2011.626784","article-title":"Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma","volume":"50","author":"Opoku-Ansah","year":"2012","journal-title":"Pharm. Biol."},{"issue":"10","key":"10.1016\/j.leukres.2019.106271_bib0225","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.21873\/anticanres.12895","article-title":"Thiasyrbactins induce cell death via proteasome inhibition in multiple myeloma cells","volume":"38","author":"Pierce","year":"2018","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.leukres.2019.106271_bib0230","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bcp.2011.06.031","article-title":"Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines","volume":"82","author":"Anshu","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.leukres.2019.106271_bib0235","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.18632\/oncotarget.24160","article-title":"Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting beta2 and beta5 subunits","volume":"9","author":"Yoshida","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2019.106271_bib0240","article-title":"Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma","author":"Robinson","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.leukres.2019.106271_bib0245","doi-asserted-by":"crossref","first-page":"35863","DOI":"10.18632\/oncotarget.16262","article-title":"Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells","volume":"8","author":"Thompson","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.leukres.2019.106271_bib0250","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/1535-7163.MCT-12-1151","article-title":"Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model","volume":"12","author":"Stessman","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.leukres.2019.106271_bib0255","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"41","key":"10.1016\/j.leukres.2019.106271_bib0260","doi-asserted-by":"crossref","first-page":"66360","DOI":"10.18632\/oncotarget.11960","article-title":"Noncanonical SQSTM1\/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming","volume":"7","author":"Riz","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.leukres.2019.106271_bib0265","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism","volume":"30","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.106271_bib0270","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.8b01884","article-title":"Structure-based design of inhibitors selective for human proteasome beta2c or beta2i subunits","author":"Xin","year":"2019","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.leukres.2019.106271_bib0275","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1021\/acs.jmedchem.9b00509","article-title":"Design and evaluation of highly selective human immunoproteasome inhibitors reveal a compensatory process that preserves immune cell viability","volume":"62","author":"Ladi","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.leukres.2019.106271_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molbiopara.2018.11.002","article-title":"Trypanosoma brucei: beta2-selective proteasome inhibitors do not block the proteasomal trypsin-like activity but are trypanocidal","volume":"227","author":"Steverding","year":"2019","journal-title":"Mol. Biochem. Parasitol."},{"issue":"2","key":"10.1016\/j.leukres.2019.106271_bib0285","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncb3289","article-title":"Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis","volume":"18","author":"Guo","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.leukres.2019.106271_bib0290","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12935-018-0574-3","article-title":"Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma","volume":"18","author":"Uhl","year":"2018","journal-title":"Cancer Cell Int."},{"issue":"32","key":"10.1016\/j.leukres.2019.106271_bib0295","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1073\/pnas.1806797115","article-title":"Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2","volume":"115","author":"Banerjee","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T08:41:56Z","timestamp":1577349716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619307167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":59,"alternative-id":["S0145212619307167"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106271","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106271"}}